Oxidien Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco

UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an unmet kidney disease indication, announced that it will present at Biotech Showcase™ 2020, to be held January 13–15 at the Hilton San Francisco Union Square, in parallel with the 38th annual J.P. Morgan Healthcare Conference.

During the presentation, Oxidien’s CEO Helena Cowley, will present recent progress as well as anticipated milestones for its hyperoxaluria program. Hyperoxaluria is a serious metabolic disorder and a risk factor for nephrolithiasis, nephrocalcinosis, and oxalate nephropathy leading to chronic kidney disease. Oxidien’s immediate focus is the continued development of an elegant oral enzymatic strategy to treat secondary hyperoxaluria. There are currently no effective approved drug therapies for any type of hyperoxaluria.